NEUROCRINE BIOSCIENCES INC 4

4 · NEUROCRINE BIOSCIENCES INC · Filed Jan 15, 2015

Form 4

Period: 2015-01-13

Director

Transactions

Exercise/Conversion
Common Stock
2015-01-13$3.40/sh+15,000$51,000→ 31,000 total
Exercise/Conversion
Common Stock
2015-01-13$7.05/sh+15,000$105,750→ 46,000 total
Sale
Common Stock
2015-01-13$30.07/sh−45,000$1,353,150→ 1,000 total
Exercise/Conversion
Nonqualified Stock Option
2015-01-13$3.07/sh−15,000$46,050→ 0 total
Exercise: $3.07Exp: 2016-05-29→ Common Stock (15,000 underlying)
Exercise/Conversion
Nonqualified Stock Option
2015-01-13$3.40/sh−15,000$51,000→ 0 total
Exercise: $3.40Exp: 2017-05-25→ Common Stock (15,000 underlying)
Exercise/Conversion
Common Stock
2015-01-13$3.07/sh+15,000$46,050→ 16,000 total
Exercise/Conversion
Nonqualified Stock Option
2015-01-13$7.05/sh−15,000$105,750→ 0 total
Exercise: $7.05Exp: 2018-05-25→ Common Stock (15,000 underlying)

Footnotes (5)

[F1]The disposition reported in this Form 4 was effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person at least 90 days prior to the transaction date in Box 3 above. Additionally, Issuer policy restricts the Reporting Person from amending, canceling, suspending or otherwise modifying any 10b5-1 trading plan subsequent to adoption of the plan.
[F2]Represents a weighted average price. These shares were sold in multiple transactions at prices ranging from $29.48 to $30.77. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.
[F3]The option was granted May 29, 2009 and vested in 12 equal monthly installments beginning June 29, 2009.
[F4]The option was granted May 25, 2010 and vested in 12 equal monthly installments beginning June 25, 2010.
[F5]The option was granted May 25, 2011 and vested in 12 equal monthly installments beginning June 25, 2011.

Documents

1 file